BG Medicine Reports Third Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BG Medicine Reports Third Quarter 2014 Financial Results

Ne t Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013

Company Retains Investment Bank to Explore Strategic Alternatives

WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc . (Nasdaq: BGMD ), the developer of the BGM Galectin-3®Test, today reported financial results for the third quarter 2014.

Third Quarter Results

The Company reported net loss for the third quarter of $2.4 million, a 35% improvement from the $3.7 million net loss reported in the prior year quarter, on total revenues of $695,000 versus total revenues of $1.0 million in the third quarter of 2013.

The decrease in total revenues reflected a $312,000 decrease in product revenues and a $23,000 decrease in service revenues from the prior year quarter. The decrease in product revenues resulted from a $141,000 decline in orders from our largest clinical laboratory customer and a $196,000 decline in purchases relating to independent research studies that were partially offset by increased revenues of $25,000, from product sales to other clinical laboratory customers. The reduction in service revenues resulted from the planned completion of the High Risk Plaque initiative in 2013 and our decision to close our research facilities in 2013 as part of our initiative to streamline the operations of the Company.

Operating expenses for the third quarter declined by 33%, or $1.4 million, from the prior year quarter. This reduction in operating expenses resulted from a decrease in research and development-related expense of $324,000 due to reduced professional fees associated with discontinued service initiatives, including the High Risk Plaque initiative, and completion of the CardioSCORE medical adjudication process, $ 706,000 reduction in sales and marketing expense related to reductions in personnel, travel expenses and other marketing expenses, and a decrease of $325,000 in general and administrative expense due to reductions in personnel, travel expenses and professional fees. These reductions were net of costs incurred in connection with the workforce reduction during the quarter.

On September 11, 2014, the Company implemented a workforce reduction of 12 people by eliminating the Company's sales and marketing organization and certain positions in other functional areas, while preserving 10 positions, including some senior management and other critical roles to support the clinical and commercial adoption of galectin-3 testing. As a result of these actions, the Company recorded total one-time charges with respect to severance payments and benefits continuation of approximately $404,000 in the third quarter of 2014, of which, $128,000, $114,000 and $162,000 was recorded in research and development, sales and marketing and general and administrative expense, respectively. Approximately $58,000 was paid during the third quarter and the remaining $346,000, included in accrued expenses, will be paid out during the fourth quarter of 2014 and the first quarter of 2015. As a result of these actions, the Company estimates it will generate annualized expense savings of approximately $1.9 million primarily from savings in employee salaries and benefits.

"We have redirected our energy and investments to prepare for the anticipated U.S. market launch of automated galectin-3 testing by our automated partners, the first of which is expected in 2015." said Paul R. Sohmer, M.D., President and Chief Executive Officer of BG Medicine. "Having already reduced our operating expenses for the first nine months of 2014 by 48% from the prior year, we eliminated approximately 55% of our work force in order to further reduce operating expenses and extend our cash runway. In so doing, we believe that we have maintained the personnel and functions that are necessary to continue to support our current customer base and to deliver on what we believe will be the critical catalysts for a successful launch of automated testing for galectin-3."

Net loss per share was $0.07 in the third quarter as compared to $0.13 in the third quarter of 2013. Cash flow used in operating activities decreased by $1.9 million, a 48% decrease, to $2.1 million in the third quarter of 2014 compared to an operating cash burn of $4.0 million in the third quarter of 2013.

For the nine months ended September 30, 2014, net loss per share was $0.21 compared to $0.52 for the same period in 2013, on total revenues of $2.2 million in the first nine months of 2014 versus total revenues of $2.9 million in the first nine months of 2013. Cash flow used in operating activities decreased by $5.7 million, a 45% decrease, to $7.1 million in the first nine months of 2014 compared to $12.8 million in the same period in 2013. At September 30, 2014, the Company's cash totaled approximately $6.3 million.

Outlook for the Remainder of 2014

"Our operating priorities are clear," continued Dr. Sohmer. "We will continue to aggressively manage our expenses and promote the clinical and commercial adoption of galectin-3 testing by generating, publishing and publicizing data derived from clinical research studies and by expanding the BGM Galectin-3 Test's labeling indications for use through additional clinical studies and clearances by the FDA. To this end, we are pleased to report that the preliminary agenda of the Scientific Sessions of the American Heart Association annual meeting convening this weekend in Chicago includes reports on nine clinical research studies that were specifically devoted to evaluating the utility of testing for galectin-3. We look forward to reporting on the results of these and other clinical research studies as they become available."

"As to our outlook for the remainder of 2014, we expect our full year 2014 revenues to be between $2.8 and $3.0 million, in light of the decrease in year-to-date revenues from our largest clinical laboratory customer and the lack of predictability of sales relating to independent research studies and notwithstanding the modest revenue growth that we are achieving from the sales of our products to the majority of our clinical laboratory customers. For the full year 2014, we continue to expect to decrease our operating cash burn as compared to 2013."

BG Medicine to Explore Strategic Alternatives

BG Medicine today announced that the Company has initiated a process to explore and consider a full range of strategic alternatives available to the Company to enhance shareholder value. The Company noted that strategic alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a merger or sale of the Company or other possible transactions.

Stifel, Nicolaus & Company, Incorporated is serving as financial advisor to BG Medicine. There can be no assurance that this exploration process will result in any transaction. The Company does not currently intend to disclose further developments with respect to this process, unless and until its Board of Directors approves a specific transaction or otherwise concludes the review of strategic alternatives.

Conferenc e Call and Web Cast

The Company will host a conference call and webcast today, November 13, 2014, beginning at 8:30 am Eastern Time. The

conference call may be accessed by dialing (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 from international locations. The conference call will also be available via the Internet at www.bg-medicine.com . Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.

Abou t BG Medicine

BG Medicine, Inc. (Nasdaq: BGMD ), the developer of the BGM Galectin-3®Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg - medicine.com .

The BG Medicine Inc. logo is available for download http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Forwar d Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements made in the section captioned "Outlook for the Remainder of 2014" and "BG Medicine to Explore Strategic Alternatives," as well as statements regarding the expected timing of the U.S. launch of the first automated galectin-3 test and our belief that we have maintained the critical personnel and functions for a successful launch of automated testing for galectin-3, following our workforce reduction. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our cash position; our ability to continue as a going concern; our history of operating losses; our ability to provide sufficient evidence of clinical utility for our galectin-3 test and to differentiate it from competing cardiovascular diagnostics tests; our ability to successfully market, commercialize and achieve widespread market penetration for our cardiovascular diagnostic tests; our ability to obtain regulatory clearance from the FDA for additional indications of our galectin-3 test; the ability of our automated partners to develop and obtain regulatory clearance of galectin-3 tests that can be performed on their automated platforms and to commercialize any such tests; our ability to generate sufficient product revenue to sustain our commercial diagnostics business; our estimates of future performance, including the expected timing of the launch of our products; our expectations regarding the impact on our galectin-3 test sales as a result of focusing our sales efforts on the hospital readmissions problem and associated penalties facing our clients; our ability to conduct the clinical studies required for regulatory clearance or approval and to demonstrate the clinical benefits and cost-effectiveness to support commercial acceptance of our products; the timing, costs and other limitations involved in obtaining regulatory clearance or approval for any of our products; the potential benefits of our products over current medical practices or other diagnostics; our ability to successfully develop, receive regulatory clearance or approval, commercialize and achieve market acceptance for any of our products; willingness of third-party payors to reimburse for the cost of our tests at prices that allow us to generate sufficient profit margins; our reliance on third parties to develop and distribute our products, including our ability to enter into collaboration agreements with respect to our products and the performance of our collaborative partners under such agreements; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the expected timing, progress or success of our research and development and commercialization efforts; our estimates regarding anticipated operating losses, future revenue, expenses, capital requirements and our needs for additional financing; our ability to recruit, hire and retain qualified personnel; the limited public float and trading volume for our common stock and volatility in our stock price; our ability to regain and maintain compliance with the continued listing requirements of The NASDAQ Capital Market; our ability to service the principal and interest amounts payable under our secured term loan facility; and other factors discussed in the Company's most recent Annual Report on Form 10-K as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission or otherwise made public. All information in this press release is as of the date of the release, and BG Medicine undertakes no duty to update this information unless required by law.

BG Medicine, Inc. and Subsidiary
Unaudited Condensed Consolidated Statements of Operations
         
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
  (in thousands, except share and per share data)
Revenues:        
Product revenues $695 $1,007 $2,233 $2,799
Service revenues -- 23  -- 125
Total revenues 695 1,030 2,233 2,924
Costs and operating expenses:        
Product costs 234 321 764 954
Service costs -- 23 -- 125
Research and development 724 1,048 1,855 3,541
Selling and marketing 647 1,353 2,069 5,279
General and administrative 1,323 1,648 3,696 5,738
Total costs and operating expenses 2,928 4,393 8,384 15,637
Loss from operations (2,233) (3,363) (6,151) 12,713)
Non-cash consideration associated with stock purchase agreement -- -- -- (329)
Interest income -- 3 2 13
Interest expense (165) (309) (597) (893)
Other income 1 4 2 8
Net loss  $ (2,397)  $ (3,665)  $ (6,744)  $ (13,914)
         
Net loss per share – basic and diluted  $ (0.07)  $ (0.13)  $ (0.21)  $ (0.52)
Weighted-average common shares outstanding used in computing per share amounts – basic and diluted 34,417,249 27,918,883 32,113,490 26,971,981
         
         
BG Medicine, Inc. and Subsidiary
Unaudited Condensed Consolidated Balance Sheets
     
  September 30, 2014 December 31, 2013
  (in thousands)
Assets    
Current assets    
Cash $6,313 $ 7,751
Accounts receivable 254 319
Inventory 358 459
Prepaid expenses and other current assets 236 306
     
Total current assets 7,161 8,835
     
Property and equipment, net 135 192
Intangible assets, net 149 192
Deposits and other assets 126 134
Total assets $7,571 $9,353
     
Liabilities and Stockholders' Equity (Deficit)    
Current liabilities    
Term loan, current portion 4,059 4,353
Accounts payable 425 965
Accrued expenses 1,252 1,993
Other current liabilities 42 39
     
Total current liabilities 5,778 7,350
     
Term loan, net of current portion -- 2,961
Other liabilities 97 111
Total liabilities 5,875 10,422
     
Stockholders' equity (deficit) 1,696 (1,069)
     
Total liabilities and stockholders' equity (deficit) $7,571 $9,353
     
     
BG Medicine, Inc. and Subsidiary
Unaudited Condensed Consolidated Statements of Cash Flows
     
  Nine Months Ended September 30,
  2014 2013
  (in thousands)
     
Net cash flows used in operating activities  $ (7,097) $ (12,820)
     
Net cash flows used in investing activities  --  (15)
     
Net cash flows from financing activities (1)  5,659 11,398
     
 Net increase in cash  (1,438) (1,437)
     
Cash, beginning of year  7,751 12,786
     
Cash, end of year   $ 6,313   $ 11,349 
     
(1)  For the nine months ended September 30, 2014, cash flows provided by financing activities include proceeds from the $10.0 million public offering. For the nine months ended September 30, 2013, cash flows provided by financing activities include proceeds from the $13.8 million public offering.

Stephen Hall, EVP & Chief Financial Officer (781) 890-1199

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 33

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Tonum and Euvita Link Supplements to Personalized Care

Updated Category News Views 14

Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 76

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Dario’s Second Women’s Health Win Tests Expansion Case

Updated Category News Views 71

Midlife care just became the newest proving ground for DarioHealth’s sales pitch. The company says The Minnesota Star Tribune has expanded its existing relationship to include Dario Women™, a program for employees navigating perimenopause and menopause. Eligible employees are expected to gain access in January 2027. For NASDAQ:DRIO, this is not some grand revenue...

Continue Reading
Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 172

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Devicie Broadens Browser Security Across Device Fleets

Updated Category News Views 23

Browsers have quietly become the front door, side door, and occasionally the busted basement window of corporate security. Devicie’s newly expanded Edge for Business Reporting Connector tackles that uncomfortable reality by pulling browser security events from Windows, macOS, iOS, and Android into the same console customers use to oversee Microsoft Intune environments....

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 63

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

Gamma Communications Celebrated for UCaaS Competitive Strategy

Updated Category News Views 342

Gamma Communications Receives Frost & Sullivan Recognition Gamma Communications has received prestigious recognition from Frost & Sullivan with the 2024 Competitive Strategy Leadership Award in the European unified communications as a service (UCaaS) industry. This award highlights the company’s exceptional strategy execution, innovative approaches, and impressive...

Continue Reading
ConocoPhillips Reports Strong Q3 2025 Results and Outlook

Updated Category News Views 232

ConocoPhillips Delivers Strong Third Quarter Performance ConocoPhillips (NYSE: COP) has once again demonstrated its robust operational capacity, reporting impressive financial results for the third quarter. Beginning with consistent execution across its production portfolio, the company's recent performance has exceeded market expectations, showcasing a continued...

Continue Reading
Electrosurgery Generators Market Set to Surge by $3.3 Billion

Updated Category News Views 125

Electrosurgery Generators Market Overview The global electrosurgery generators market is on an impressive growth trajectory, projected to reach USD 3,359.2 million by 2035. As healthcare evolves, this market is driven by innovations and a rising preference for minimally invasive procedures. The surge in outpatient surgical centers and advancements in electrosurgical...

Continue Reading
Explore the Versatile Applications of INNOVERA™ at Lineapelle Milan

Updated Category News Views 322

Discover INNOVERA™ at Lineapelle Milan 2026 Modern Meadow, a pioneer in bio-design, is set to showcase their groundbreaking material, INNOVERA™, at the highly anticipated Lineapelle Milan 2026. This prominent international leather fair will provide a platform for the company to illustrate the dynamic capabilities of INNOVERA™ across various industries. A Revolution...

Continue Reading
Harnessing AI for Enhanced Military Logistics Efficiency

Updated Category News Views 174

Virtualitics Secures Phase II Contract with AFGSC Virtualitics has recently been awarded a significant contract with the U.S. Air Force Global Strike Command (AFGSC). This Small Business Innovation Research (SBIR) Phase II contract aims to optimize logistics using artificial intelligence (AI) for Readiness Spares Package (RSP) mobilization. This initiative is crucial to...

Continue Reading